866-997-4948(US-Canada Toll Free)

Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2018

Published By :

GlobalData

Published Date : Jun 2018

Category :

Pharmaceutical

No. of Pages : 383 Pages

Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2018" provides an overview of Relapsed Acute Myeloid Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Acute Myeloid Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Relapsed Acute Myeloid Leukemia 31
Jun 26, 2018: Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial 31
Jun 16, 2018: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyos Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations 32
Jun 15, 2018: Tolero Pharmaceuticals Presents Clinical Data for Investigational Agent Alvocidib in Patients with Relapsed Refractory MCL-1-Dependent AML at EHA 2018 32
Jun 13, 2018: Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M 33
Jun 12, 2018: EHA Late-Breaking, Plenary Presentation: Quizartinib Significantly Prolongs Overall Survival in Pivotal, Phase 3 AML Study 33
Jun 06, 2018: Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018 34
Jun 02, 2018: Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent 35
May 17, 2018: Forty Seven to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association 35
May 17, 2018: BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients 36
May 16, 2018: Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center 36
May 16, 2018: Agios to Present Clinical Data on Ivosidenib at ASCO 36
May 15, 2018: Race executes agreement for Bisantrene clinical trial 37
May 08, 2018: Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study) 37
May 01, 2018: Aptevo Therapeutics Announces IND Submission for APVO436 38
Apr 27, 2018: Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient 38
Apr 16, 2018: Selvita publishes research results on SEL24 in Oncotarget 38
Apr 12, 2018: Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia 39
Apr 09, 2018: Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018 39
Clinical Trial Profile Snapshots 41
Appendix 380
Abbreviations 380
Definitions 380
Research Methodology 381
Secondary Research 381
About GlobalData 382
Contact Us 382
Disclaimer 382
Source 383

List of Tables
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2018* 8
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2018* 19
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

List of Figures
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Relapsed Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Relapsed Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2018* 19
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Relapsed Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
Relapsed Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Relapsed Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Relapsed Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
GlobalData Methodology 381

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *